Craig-Hallum raised the firm’s price target on Koru Medical (KRMD) to $6 from $5 and keeps a Buy rating on the shares. Koru Medical’s Q4 pre-release points to another “nice” quarter for the company, and a cash flow positive one, the analyst tells investors in a research note. The firm is focused on continued commercial execution and international expansion to drive above market growth in 2025.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.